{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:50:58Z","timestamp":1777481458043,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","award":["2023-2"],"award-info":[{"award-number":["2023-2"]}],"id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","award":["A2024001"],"award-info":[{"award-number":["A2024001"]}],"id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10120-025-01704-9","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:22:35Z","timestamp":1773062555000},"page":"578-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and tissue distribution advantages of intraperitoneal oxaliplatin over systemic delivery: a swine model comparison of PIPAC and HPIPAC"],"prefix":"10.1007","volume":"29","author":[{"given":"Mira","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-0048","authenticated-orcid":false,"given":"Hyung-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Du-Yeong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanmi","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duk Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yooseong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"1704_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","volume":"243","author":"MJ Koppe","year":"2006","unstructured":"Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin. Ann Surg. 2006;243:212\u201322.","journal-title":"Ann Surg"},{"key":"1704_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ygyno.2018.01.030","volume":"149","author":"C-I Liao","year":"2018","unstructured":"Liao C-I, Chow S, Chen L-M, Kapp DS, Mann A, Chan JK. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. Gynecol Oncol. 2018;149:318\u201323.","journal-title":"Gynecol Oncol"},{"key":"1704_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138.","journal-title":"Int J Cancer"},{"key":"1704_CR4","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1245\/s10434-018-6335-7","volume":"25","author":"LA Lambert","year":"2018","unstructured":"Lambert LA, Wiseman J. Palliative management of peritoneal metastases. Ann Surg Oncol. 2018;25:2165\u201371.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5230\/jgc.2023.23.e11","volume":"23","author":"T-H Kim","year":"2023","unstructured":"Kim T-H, Kim I-H, Kang SJ, Choi M, Kim B-H, Eom BW, et al. Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer. 2023;23:3\u2013106.","journal-title":"J Gastric Cancer"},{"key":"1704_CR6","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"1704_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42:1123\u201331.","journal-title":"Eur J Surg Oncol"},{"key":"1704_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4.","journal-title":"Cancer Treat Res"},{"key":"1704_CR9","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"1704_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2020.02.004","volume":"163\u2013164","author":"ALB Seynhaeve","year":"2020","unstructured":"Seynhaeve ALB, Amin M, Haemmerich D, van Rhoon GC, ten Hagen TLM. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv Drug Deliv Rev. 2020;163\u2013164:125\u201344.","journal-title":"Adv Drug Deliv Rev"},{"key":"1704_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","volume":"24","author":"M Markman","year":"2006","unstructured":"Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988\u201394.","journal-title":"J Clin Oncol"},{"key":"1704_CR12","first-page":"802","volume":"108","author":"P Piso","year":"2011","unstructured":"Piso P, Arnold D. Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int. 2011;108:802\u20138.","journal-title":"Dtsch Arztebl Int"},{"key":"1704_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","volume":"20","author":"DKA Chia","year":"2020","unstructured":"Chia DKA, So JBY. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020;20:115\u201326.","journal-title":"J Gastric Cancer"},{"key":"1704_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","volume":"15","author":"D Baratti","year":"2008","unstructured":"Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526\u201334.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR16","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1007\/s00464-015-4738-0","volume":"30","author":"DH Jung","year":"2016","unstructured":"Jung DH, Son SY, Oo AM, Park YS, Shin DJ, Ahn S-H, et al. Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc. 2016;30:4258\u201364.","journal-title":"Surg Endosc"},{"key":"1704_CR17","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1007\/s00464-024-10702-4","volume":"38","author":"S-H Min","year":"2024","unstructured":"Min S-H, Yoo M, Hwang D, Lee E, Kang SH, Lee S, et al. Hyperthermic pressurized intraperitoneal aerosol drug delivery system in a large animal model: a feasibility and safety study. Surg Endosc. 2024;38:2062\u20139.","journal-title":"Surg Endosc"},{"key":"1704_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5230\/jgc.2024.24.e24","volume":"24","author":"S-H Min","year":"2024","unstructured":"Min S-H, Lee J, Yoo M, Hwang D, Lee E, Kang SH, et al. Efficacy of hyperthermic pressurized intraperitoneal aerosol chemotherapy in an in vitro model using a human gastric cancer AGS cell line and an abdominal cavity model. J Gastric Cancer. 2024;24:246\u201356.","journal-title":"J Gastric Cancer"},{"key":"1704_CR19","doi-asserted-by":"publisher","unstructured":"Guide for the Care and Use of Laboratory Animals: Eighth Edition [Internet]. Washington, D.C.: National Academies Press; 2011 [cited 2025 Apr 28]. https:\/\/doi.org\/10.17226\/12910","DOI":"10.17226\/12910"},{"key":"1704_CR20","first-page":"7037","volume":"37","author":"T Masuishi","year":"2017","unstructured":"Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S, et al. FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37:7037\u201342.","journal-title":"Anticancer Res"},{"key":"1704_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/SLA.0b013e3182193143","volume":"254","author":"N Pich\u00e9","year":"2011","unstructured":"Pich\u00e9 N, Leblond FA, Sid\u00e9ris L, Pichette V, Drolet P, Fortier L-P, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138.","journal-title":"Ann Surg"},{"key":"1704_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/SLA.0b013e3182582b38","volume":"256","author":"O Facy","year":"2012","unstructured":"Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, et al. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg. 2012;256:1084\u20138.","journal-title":"Ann Surg"},{"key":"1704_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","volume":"28","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Tajzai R, Rovers KP, Wassenaar ECE, Moes DJAR, Pluimakers G, et al. Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol. 2021;28:265\u201372.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1515\/pp-2017-0015","volume":"2","author":"C Eveno","year":"2017","unstructured":"Eveno C, Haidara A, Ali I, Pimpie C, Mirshahi M, Pocard M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum. 2017;2:103\u20139.","journal-title":"Pleura Peritoneum"},{"key":"1704_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10120-020-01101-4","volume":"24","author":"K-W Lee","year":"2021","unstructured":"Lee K-W, Chung I-J, Ryu M-H, Park YI, Nam B-H, Oh H-S, et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. 2021;24:156\u201367.","journal-title":"Gastric Cancer"},{"key":"1704_CR26","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1039\/D0NA00708K","volume":"2","author":"ACK Chung","year":"2020","unstructured":"Chung ACK, Li X, Li W-C, Wang T, Lee H-K, Jin L, et al. Mass spectrometry imaging and monitoring of in vivo glutathione-triggered cisplatin release from nanoparticles in the kidneys. Nanoscale Adv. 2020;2:5857\u201365.","journal-title":"Nanoscale Adv"},{"key":"1704_CR27","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139.","journal-title":"J Clin Oncol"},{"key":"1704_CR28","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28:3863\u201370.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-003-0680-2","volume":"52","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1704_CR30","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1245\/s10434-007-9348-1","volume":"14","author":"D Elias","year":"2007","unstructured":"Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818\u201324.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"key":"1704_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2:116\u201323.","journal-title":"Ann Gastroenterol Surg"},{"key":"1704_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/cancers14030570","volume":"14","author":"BJ Sun","year":"2022","unstructured":"Sun BJ, Lee B. Review of regional therapies for gastric cancer with peritoneal metastases. Cancers. 2022;14:570.","journal-title":"Cancers"},{"key":"1704_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1083\/jcb.200910104","volume":"188","author":"E Ruoslahti","year":"2010","unstructured":"Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759\u201368.","journal-title":"J Cell Biol"},{"key":"1704_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/MO:19:4:261","volume":"19","author":"H Ehrsson","year":"2002","unstructured":"Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol Northwood Lond Engl. 2002;19:261\u20135.","journal-title":"Med Oncol Northwood Lond Engl"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01704-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:12:35Z","timestamp":1777385555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01704-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01704-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pf. Hyung-Ho Kim has received research grant from Chuang-Ang University in 2023 and Institute of Clinical Medicine, Chung-Ang University Gwangmyeong Hospital in 2024. He is founder and CEO of Silver Lining Medical Inc., which provided funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}